Recent studies of the epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United
States have confirmed its status as the predominant pathogen associated with invasive skin and soft tissue infections in both the community and health care settings (12, 14) . The emergence and spread of invasive MRSA isolates, including those exhibiting multidrug-resistant traits (15) , have spurred renewed interest in the potential use of older classes of antistaphylococcal agents for the treatment of serious infections. In an accompanying article (18) , we describe detailed mode-of-action studies for CBR-2092, a novel rifampinquinolone hybrid antibiotic that combines the rifamycin SV and a 4H-4-oxo-quinolizine pharmacophores via a chiral linking group.
Biochemical studies indicate that CBR-2092 exhibits rifampin-like potency as an inhibitor of RNA polymerase and is an equipotent (or balanced) inhibitor of DNA gyrase and DNA topoisomerase IV that retains activity against a prevalent quinolone-resistant variant. Macromolecular biosynthesis studies confirm that CBR-2092 causes rifampin-like effects on RNA and protein synthesis in rifampin-susceptible strains and quinolone-like effects on DNA synthesis in rifampin-resistant strains. Finally, data from studies on the isolation and characterization of mutant strains that exhibit reduced susceptibility to CBR-2092 substantiated that RNA polymerase is the primary cellular target of CBR-2092, with DNA gyrase and DNA topoisomerase IV being secondary and tertiary targets, respectively, in strains exhibiting preexisting rifampin resistance. In contrast to quinolone comparator agents, strains with altered susceptibility to CBR-2092 were not found to exhibit changes consistent with altered efflux properties (18) . Overall, the combined data suggest that CBR-2092 may have potential utility as monotherapy for the treatment of S. aureus infections and those mediated by other susceptible cocci. Here we describe the results of microbiology studies conducted to further characterize the in vitro profile of activity of CBR-2092 against staphylococci and streptococci and to compare its activity to the activities of antibiotics of the parental rifamycin and fluoroquinolone classes. Table 1 . The isolation and characterization of derivatives of S. aureus ATCC 29213 (CB190) that exhibit stable resistance to agents of the rifamycin or quinolone classes are described in the accompanying article (18) . Derivatives of Streptococcus pyogenes CB1208 that exhibit intermediate resistance (i.e., MIC, 1 g/ml; strain CB1456) or high-level resistance (i.e., MIC, Ͼ32 g/ml; strain CB1504) to rifampin were isolated sequentially by spontaneous selection on Trypticase soy agar medium supplemented with 5% sheep's blood (TSBA) and 1 or 16 g/ml rifampin, respectively. Genotypic analysis of these strains was undertaken by standard methods (18) .
Deletion-replacement of the hemB locus for the generation of a stable S. aureus small colony variant (17, 25) was accomplished by the pKOR1-mediated allelic replacement methodology (2) . Briefly, a linear ⌬hemB::ermC amplicon was generated by splicing-overlap extension PCR methods with oligonucleotide primers specific for the 5Ј and 3Ј flanking regions of hemB or for the ermC coding sequence and promoter region originally obtained from pMP963 (11) . Outside primers were engineered to also carry site-specific recombination attB sites for recombination into pKOR1 (2) . Deletion-replacement of hemB was accomplished by allelic replacement with a pKOR1-based ⌬hemB::ermC construct with selection on hemin (1 g/ml)-supplemented medium with anhydrotetracycline (1 g/ml) and erythromycin (2 g/ml). A single erythromycin-resistant, chloramphenicol-sensitive recombinant (designated CB1927) was identified and was subsequently confirmed to bear the appropriate ⌬hemB::ermC deletion-replacement mutation by diagnostic PCR analysis with outside flanking oligonucleotide primers.
Determination of MICs. Determination of MICs was done in accordance with the Clinical and Laboratory Standards Institute (CLSI) methodology (3) either by the broth microdilution method with cation-adjusted Mueller Hinton (MHII) medium further supplemented with 0.002% (vol/vol) polysorbate 80 (P-80) (18) or by the agar dilution method with MHII agar medium without P-80 supplementation.
Determination of bactericidal activity. Bactericidal activity was assessed by determining minimum bactericidal concentration (MBC) endpoints and by timekill assays (8) . The MBC was determined on charcoal agar medium following assessment of the broth microdilution MIC after 18 to 24 h of incubation, with the MBC defined as the lowest consecutive drug concentration that resulted in a Ն99.9% (3-log 10 ) reduction in the starting inoculum in terms of the input CFU. Standard-or high-initial-cell-density time-kill studies employed log-phase cultures of S. aureus which were diluted into prewarmed 37°C MHII broth medium with 0.002% P-80 to yield starting initial cell densities of Ϸ10 6 and 10 8 CFU/ml, respectively. Antimicrobial agents were then added from 100ϫ the final desired dose in dimethyl sulfoxide aliquots to yield the indicated final test concentrations. Growth or killing was measured following serial dilution in physiologic saline and enumeration of the viable CFU recovered after 20 h of incubation on charcoal agar medium. To test for the emergence of resistant subpopulations, samples were also plated on MHII agar further supplemented with either rifampin at 1 g/ml or ciprofloxacin at 1 or 4 g/ml. All time-kill assays involving staphylococci were conducted under ambient atmospheric conditions in six-well tissue culture plates at 37°C with aeration to ensure consistent and robust growth. For time-kill studies with Streptococcus pyogenes, cells were harvested following overnight growth on TSBA plates and were suspended for assay in MHII broth with 0.002% P-80 but without lysed horse blood. S. pyogenes was grown statically at 35°C in an atmosphere of 5 to 10% CO 2 , with viable counts determined on TSBA following dilution in physiologic saline.
Spontaneous resistance selection methods. Mutant prevention concentrations (MPCs) were determined by plating 10 10 viable test organisms on MHII agar medium with twofold doubling concentrations of antibiotic. The MPC was defined as the lowest consecutive drug concentration capable of fully suppressing the emergence of antibiotic-resistant bacterial subpopulations (5). The resistance frequency was similarly determined by plating 10 12 viable organisms (CFU) on a series of agar plates containing a fixed dose of 1 g/ml of the test agent.
In vitro PAEs and SMEs. Studies were undertaken to measure postantibiotic effects (PAEs) and sub-MIC effects (SMEs) on S. aureus CB190 (ATCC 29213) or S. epidermidis CB191 (ATCC 35984) cultivated in MHII broth supplemented with P-80. The PAE period was determined following the exposure of log-phase bacteria (Ϸ10 7 to 10 8 CFU/ml) to 3ϫ MIC for 1 h and 0.5 h for S. aureus CB190 (ATCC 29213) and S. epidermidis CB191, respectively, in which drug was removed by a 10 Ϫ3 dilution method as described previously (4) . The PAE-SME was determined by exposure to a 3ϫMIC concentration for 1 h or 0.5 h, followed by 10 Ϫ3 dilution into medium containing the indicated test agents at a final concentration of 0.125ϫ MIC. The SME was determined in parallel by 10 Ϫ3 dilution of non-drug-exposed control cultures into medium containing the indicated test agents at a final concentration of 0.125ϫMIC. Viable counts were determined on charcoal agar medium following serial dilution in physiologic saline. Intracellular killing assays. Intracellular killing studies employed the adherent, mouse macrophage cell line J774A.1 (ATCC TIB-67) in combination with S. aureus CB1406 (ATCC 25923) or a small colony variant derived from S. aureus ATCC 12600 bearing a deletion-replacement ⌬hemB::ermC mutation (CB1927). The bacteria were opsonized with 10% normal mouse serum prior to infection and seeded at a multiplicity of infection of 4:1. To ensure bacterium-macrophage surface contact, the plates were centrifuged briefly at 500 ϫ g and phagocytosis of the bacterial cells was allowed to proceed for 1 h at 37°C in 5% CO 2 . After phagocytosis, the cell monolayer was washed two times with sterile prewarmed growth medium and replaced with complete growth medium containing an antimicrobial at the indicated test concentration to remove/inactivate any remaining extracellular and adherent nonphagocytosed bacteria. The effect of drug treatment on intracellular bacterial viability was measured by direct viable count measurements following deoxycholate-mediated cell disruption, serial dilution in sterile saline, and enumeration of the viable CFU on charcoal agar following appropriate incubation. In the experiments reported here, the initial intracellular inoculum quantified was typically in the range of 1 ϫ 10 6 to 3 ϫ 10 6 CFU per ml. The absence of extracellular S. aureus growth or contamination was monitored in parallel by sampling the cell culture medium at each time point. Table 2 lists the in vitro antimicrobial activity of CBR-2092 against 175 staphylococci and 125 streptococci compared to the activities of rifampin and ciprofloxacin determined in parallel. The broth microdilution CBR-2092 MIC 90 s for MSSA, MRSA, MSSE, or MRSE isolates were 0.015, 0.015, 0.008, and 0.5 g/ml, respectively. The activity of CBR-2092 against MSSA, MRSA, and MSSE was equivalent to that of rifampin and was improved over that of ciprofloxacin, whereas the activity of CBR-2092 was improved over the activities of both rifampin and ciprofloxacin against MRSE. The MIC 90 s of CBR-2092 for S. pyogenes, S. agalactiae, and S. pneumoniae were 0.12, 0.25, and 0.12 g/ml, respectively, and, again, were equivalent to those of rifampin and improved over those of ciprofloxacin.
RESULTS

Activity of CBR-2092 and comparators against clinical isolates of primary target pathogens.
While enterococci were not primary target pathogens, the activity of CBR-2092 against enterococci was evaluated in studies with limited numbers of clinical isolates (n ϭ 10) and yielded MIC 90 s for rifampin and CBR-2092 of 8 and 2 g/ml, respectively, for Enterococcus faecalis and 8 and 1 g/ml, respectively, for Enterococcus faecium (data not shown). The mechanistic basis underlying the lower susceptibility of enterococci to rifamycins and, to a lesser degree, CBR-2092 compared to those of other gram-positive cocci is not well understood but may reflect lower cell surface penetration.
Correlation between MIC and MBCs. As shown in Table 3 , the MBCs for CBR-2092 and the comparators were evaluated by using S. aureus CB190 (ATCC 29213) and otherwise isogenic derivatives bearing a high-level rifamycin resistance mutation in rpoB (rpoB H481Y ) and/or quinolone resistance mutations in both gyrA (gyrA S84L ) and parC (parC S80F ). The MICs for rifampin against the rifamycin-susceptible strains were 0.008 g/ml; however, rifampin exhibited only bacteriostatic activity in these assays, and no MBC endpoints were determined in the concentration range tested here (i.e., up to 4 g/ml). Ciprofloxacin, in contrast, exhibited bactericidal activity against quinolone-susceptible strains, with equivalent MICs and MBCs of 0.24 g/ml. The MIC determined for CBR-2092 against a rifampin-and quinolone-susceptible strain was 0.008 g/ml, and thus, CBR-2092 had potency equivalent to that of rifampin. However, unlike rifampin, an MBC of 1 g/ml was determined, indicating that CBR-2092 exhibits bactericidal activity that is not accounted for by its rifamycin pharmacophore alone ( Table 3 ). The CBR-2092 MIC for rifampin-resistant strain CB370 (rpoB H481Y ) was 0.12 g/ml and, in this context, was bactericidal in nature, with an equivalent MBC of 0.12 g/ml. The notion that the quinolone pharmacophore of CBR-2092 is responsible for the apparent bactericidal activity exhibited against strain CB370 (rpoB H481Y ) is substantiated by the a Cidality was considered paradoxical (i.e., the drug is less cidal at higher doses; Fig. 1 ).
observation that the MBC determined for strain CB815 (rpoB H481Y gyrA S84L parC S80F ) is Ͼ4 g/ml. Bactericidal activity in time-kill assays. In the standard time-kill assay format, when ciprofloxacin was dosed at Ն1 g/ml, it was rapidly cidal and promoted a 3-log 10 (99.9%) reduction in the CFU of wild-type S. aureus CB190 (ATCC 29213) within 2 to 3 h (Fig. 1C) . In contrast, rifampin dosed in the same fashion failed to achieve a 3-log 10 cidal endpoint within the 24-h time period (Fig. 1B) and, as such, behaved as a bacteriostatic agent. CBR-2092 exhibited time-kill properties that were distinct from and intermediate between those of ciprofloxacin and rifampin. At fixed drug doses of 0.1, 1, or 10 g/ml of CBR-2092, 3-log 10 CFU reductions in wild-type S. aureus CB190 (ATCC 29213) were recorded in 24-h, 10-h, and 3-h increments, respectively (Fig. 1A) ; and as such, CBR-2092 exhibited attributes of both time-and concentration-dependent killing in vitro. As expected, rifampin lacked any appreciable antimicrobial activity against the rifamycin-resistant strain CB370 or CB815 (Fig. 1E and K) , whereas ciprofloxacin was similarly ineffective againt strain CB814 or CB815 bearing quinolone resistance owing to specific mutations in parC S80F and gyrA S84L (Fig. 1I  and L) . In contrast, CBR-2092 exhibited markedly better activity than ciprofloxacin (compare Fig. 1G and I ) and better overall cidality than equivalently dosed rifampin against quinolone-resistant strain CB814 (compare Fig. 1G and H) . Similarly, CBR-2092 exhibited activity superior to that of rifampin against high-level rifampin-resistant strain CB370 (compare Fig. 1D and E) and achieved cidal 3-log 10 -CFU reductions at CBR-2092 concentrations of 10, 1, and 0.1 g/ml within 24, 6, and 4 h, respectively. Such paradoxical cidality has been reported previously for quinolone agents in studies with a variety of gram-positive cocci. As this paradoxical killing is observed with CBR-2092 only with highly rifampin-resistant strains, it seems likely that only the quinolone pharmacophore of CBR-2092 is necessary and that ongoing RNA synthesis is a contributory factor. Finally, CBR-2092 exhibited bactericidal activity against rifamycin-resistant and quinolone-resistant strain CB815 that was superior to the activities of both rifampin and ciprofloxacin (compare Fig. 1J to K and L). Less overall killing was again observed at 10 g/ml, indicating a possible paradoxical bactericidal effect of CBR-2092 in this genetic background.
A comparison of the time-kill properties exhibited by CBR-2092, rifampin, and ciprofloxacin against S. epidermidis CB191 (ATCC 35984) and S. aureus CB190 (ATCC 29213) is shown in Fig. 2 , which shows the results of studies in which the compounds were dosed at multiples of their respective MICs. As expected from precedents described in the literature, rifampin exhibited more rapid bactericidal characteristics against S. epidermidis CB191 (ATCC 35984) than against S. aureus CB190 (ATCC 29213). However, for both S. aureus and S. epidermidis, rifampin resistance emerged at either 1ϫ or 2ϫMIC (data not shown), and the rebound of viable cells was observed in the 2ϫ to 8ϫMIC range with S. epidermidis (Fig. 2E) . CBR-2092 also exhibited more pronounced cidality against S. epidermidis but was distinguished from rifampin in that no resistance development was observed and no rebound of the treated cultures occurred (Fig. 2D) . The activities of CBR-2092 against a clinical isolate of Streptococcus pyogenes (CB1208) and two otherwise isogenic strains bearing intermediate or high-level resistance to rifampin are shown in Fig. 3 . Against the rifampin-sensitive parent strain (CB1208), CBR-2092 exhibited time-dependent cidal properties but failed to achieve a 3-log 10 killing following 24 h of incubation (Fig. 3A) . However, against strain CB1456, a derivative of CB1208 that exhibits intermediate-level resistance to rifampin (MIC of 1 g/ml) and that bears the rpoB A624D mutation, CBR-2092 exhibited bactericidal activity, with elements of both time and concentration dependence, and achieved a killing of Ն99.9% (or Ն3 log 10 ) at Ն2ϫ MIC following Յ24 h of exposure (Fig. 3B ). This effect was further pronounced in strain CB1504, a derivative of S. pyogenes CB1456 that exhibits high-level resistance to rifampin (MIC Ͼ 32 g/ml) and that bears the rpoB H486Y mutation, in addition to rpoB A624D . In this background, CBR-2092 achieved a killing of Ն99.9% (or Ն3 log 10 ) at Ն4ϫ MIC following Յ6 h of exposure, suggesting that the bactericidal properties of CBR-2092 are further enhanced against this strain that exhibits highlevel resistance to rifampin (Fig. 3C ). This effect might be anticipated if the relative contribution of the fluoroquinolone pharmacophore is in effect further elevated owing to the more complete genetic silencing of the target of the rifamycin pharmacophore. The resulting effect is a shift in the relative timekill properties of CBR-2092 toward a more fluoroquinolonelike activity with bactericidal activity that, again, has elements of both time and concentration dependence. Overall, these combined data are consistent with the anticipated properties of a rifamycin-fluoroquinolone hybrid antibacterial agent with antimicrobial contributions from both of its composite pharmacophores.
Single-step resistance studies. MPCs and spontaneous resistance frequencies were determined for CBR-2092, rifampin, and ciprofloxacin against S. aureus CB190 (ATCC 29213). In these studies, concentrations of rifampin up to 32 g/ml were insufficient to prevent the emergence of rifamycin resistance following the plating of 10 10 viable CFU, and the resistance frequency for rifampin at the 1 g/ml concentration was determined to be 2.9 ϫ 10 Ϫ8 (Table 4 ). In contrast, the MPCs for ciprofloxacin and CBR-2092 were 2 g/ml and 0.12 g/ml, respectively. These data allow the calculation of mutant selection windows (MSWs), which are the MPC/MIC ratios (26) , and yield much smaller MSW values (i.e., eightfold) for ciprofloxacin and CBR-2092 than that apparent for rifampin (i.e., Ͼ4,000). These data are in accordance with those from studies with S. aureus RN4220, for which MSW values of 13 and 160,000 were determined for ciprofloxacin and rifampin, respectively (26) . Finally, ciprofloxacin dosed at 1 g/ml exhibited an observed resistance frequency of 5 ϫ 10 Ϫ9 , whereas no resistant mutants were recovered for CBR-2092 at this concentration, indicating an apparent resistance frequency of Ͻ10 Ϫ12 . These combined data are consistent with the proposed multitargeting nature of CBR-2092 and hold promise for a low potential for spontaneous resistance development.
In vitro PAEs and SMEs. CBR-2092 exhibited in vitro PAEs against S. aureus CB190 (ATCC 29213) and S. epidermidis CB191 (ATCC 35984) that were similar to those of rifampin and improved over those of ciprofloxacin ( Fig. 4A and D ; Table 5 ). However, unlike rifampin, CBR-2092 exhibited prolonged postantibiotic SMEs (PA-SME) and SMEs against S. aureus CB190 (ATCC 29213) (Fig. 4B and C) that were consistent with the efficient cell penetration and/or retention of CBR-2092. Interestingly, such dramatic SMEs were not simi- larly observed for S. epidermidis (ATCC 35984) ( Fig. 4E and  F) , possibly reflecting the improved cidality of CBR-2092 in the latter case. Impact of intrinsic or mutationally elevated efflux systems. In order to determine the possible effect of the NorA and/or MepA efflux system on CBR-2092, MIC assays were conducted with S. aureus strains that exhibit mutationally activated NorA or MepA efflux activity (strains CB990 and SA-K2068, respectively) or basal NorA or MepA efflux activity (CB190 and SA-8325-4, respectively) ( Table 6 ). MICs for rifampin were equivalent between otherwise isogenic strain pairs (strains CB990 and CB190 and strains SA-K2068 and SA-8325-4), and it was concluded that rifampin is not a substrate for the NorA or MepA efflux system. In contrast, and consistent with precedents described in the literature, the quinolone agents tested were differentially affected by the mutationally elevated NorAand/or MepA-mediated efflux activity in S. aureus (strains CB990 versus CB190 and strains SA-K2068 versus SA-8325-4 in Table 6 ). In contrast, CBR-2092, like rifampin, did not appear to be a substrate for either the NorA or the MepA efflux system, and as such, its MIC was equivalent between otherwise isogenic pairs of strains (strains CB990 and CB190 a PAEs were determined with 3ϫ MIC for 1 h, PA-SMEs were determined with 3ϫ MIC for 1 h for the PAE and 0.125ϫ MIC for the SME, and SMEs were determined with 0.125ϫ MIC.
b Determined by the broth microdilution method in MHII broth with 0.002% (vol/vol) P-80. c -, no measured effect was observed.
and strains SA-K2068 and SA-8325-4) that exhibit mutationally activated or intrinsic basal efflux pump activity. The conclusion that CBR-2092 is not a substrate for NorA-or MepAmediated efflux in S. aureus is substantiated by the observation that the mutational activation of efflux systems does not appear to be a contributory factor in the stepwise development of resistance to CBR-2092 (18) . Suppression of rifampin resistance emergence in high-celldensity time-kill assays. Time-kill assays were also conducted with seed cultures with a high initial cell density (Ϸ10 8 CFU per ml) that allowed the outgrowth of spontaneous rifampinresistant subpopulations present in the starter population. As shown in Fig. 5B , dosing with rifampin at 1 g/ml (ϳ125ϫ MIC) resulted in an initial drop in the numbers of viable CFU by 4 h but failed to suppress the emergence of rifampin-resistant subpopulations, such that by 48 h, essentially 100% of the recovered cells exhibit resistance to rifampin. The quinolone agents (i.e., ciprofloxacin, levofloxacin, and moxifloxacin) FIG. 5 . Time-kill studies conducted with a high initial cell density. The influence of the S. aureus CB190 (ATCC 29213) cell density on the antimicrobial activities and resistance development potential of CBR-2092, rifampin, quinolones, or cocktails of rifampin (Rif) plus quinolones (Quin) was determined in time-kill assays. All quinolones were dosed at their respective CLSI resistance breakpoints, rifampin was dosed at 1 g/ml, and CBR-2092 was dosed at 0.25 and 4 g/ml. Symbols: closed circles, control (no drug); open circles, rifampin (1 g/ml) ; open triangles, CBR-2092 (0.25 g/ml); closed triangles, CBR-2092 (4 g/ml); open squares, ciprofloxacin (4 g/ml); open downward triangles, levofloxacin (4 g/ml); open diamonds, moxifloxacin (2 g/ml); closed squares, rifampin (1 g/ml) plus ciprofloxacin (4 g/ml); closed downward triangles, rifampin (1 g/ml) plus levofloxacin (4 g/ml); closed diamonds, rifampin (1 g/ml) plus moxifloxacin (2 g/ml); open circles, dashed line, rifampin-resistant CFU recovered. on August 28, 2017 by guest http://aac.asm.org/ dosed here were tested alone at their respective CLSI resistance breakpoints; they were appreciably bactericidal and did not select for measured quinolone resistance (Fig. 5C ). The combination of rifampin and ciprofloxacin, levofloxacin, or moxifloxacin suppressed the emergence of a rifampin-resistant subpopulation (data not shown) but was markedly less cidal than the individual quinolone agents when they were tested alone (compare Fig. 5C and D) . The in vitro antagonism of quinolone cidality by rifamycins and translation inhibitors has been well documented in studies of gram-positive cocci and is best explained by the requirement for de novo RNA and/or protein synthesis as a key step in the process of quinolonemediated, bacterial cell killing (7, 13) . In contrast, CBR-2092, dosed here at 0.25 g/ml or 4 g/ml, retained excellent cidal activity and also suppressed the emergence of rifampin-resistant subpopulations (Fig. 5A) . Such results are wholly consistent with the multifunctional activity of CBR-2092 and an apparent lack of self-antagonism. Intracellular activity against wild-type or genetically defined small colony variants of S. aureus. Staphylococci are capable of stably residing within eukaryotic cells such as macrophages and monocytes, and it is postulated that such organisms represent reservoirs of sequestered bacteria that may contribute to persistent and recurrent infections (16) . In light of the utility of the rifamycin class of agents for the treatment of persistent intracellular infections, we investigated the ability of CBR-2092 to eradicate S. aureus cells growing in cultured J774A.1 murine macrophages. During the first 2 h, CBR-2092 exhibited excellent intracellular activity against wild-type S. aureus CB1406 (ATCC 25923) that was similar to that seen for the potent quinolone moxifloxacin when it was tested against this quinolone-sensitive S. aureus strain (Fig. 6A) . However, unlike moxifloxacin, CBR-2092 also exhibited protracted rifampinlike bactericidal activity that persisted through 24 h, resulting in a Ͼ99% cell reduction in ϳ14 h (Fig. 6A) . Such results are consistent with the effective accumulation and retention of CBR-2092 in subcellular compartments occupied by reservoirs of viable intracellular staphylococci. In contrast, gentamicin, which exhibits poor intracellular accumulation, exhibited little effect on the viability of the intracellular staphylococci. The intracellular killing activity of CBR-2092 (dosed at 4 g/ml) was also improved over that of a rifampin-plus-moxifloxacin cocktail (dosed at 4 g/ml of each agent), and evidence of rifampin-mediated antagonism of early rapid moxifloxacin cidality was again apparent for the cocktail combination (Fig. 6A) .
Finally, CBR-2092 exhibited markedly improved intracellular killing activity relative to that of the comparators tested when their activities against an engineered ⌬hemB::ermC mutant (CB1927) which exhibits hemin auxotrophy and a small colony variant phenotype (Fig. 6B) were assayed (24) . This observation is quite striking, as clinical isolates that exhibit a small colony variant phenotype have been implicated in a variety of persistent bacterial infections, including those of indwelling medical devices, and are typically recalcitrant to current antimicrobial therapies (17) .
DISCUSSION
CBR-2092 exhibits potent activity against prevalent staphylococcal and streptococcal pathogens associated with skin and soft tissue infections, hospital-and community-acquired pneumonia, bloodstream infections, and biofilm-associated infections of indwelling medical devices. Importantly, activity is retained against the MRSA and MRSE populations prevalent among the staphylococci. For the MRSA and MRSE isolates, the MIC ranges determined for CBR-2092 and rifampin were Յ0.004 to 2 and Յ0.004 to Ͼ4 g/ml, respectively, and for a number of isolates the rifampin MICs were highly elevated (data not shown). As quinolone resistance is more prevalent in MRSA and MRSE strains, it will be important to understand and monitor the incidence of coresistance to rifamycins and quinolones in these key pathogens to elucidate the impact of such on the potential future clinical utility of CBR-2092.
Data from a series of assays indicate that CBR-2092 exhibits bactericidal properties against staphylococci that are consistent with those expected of a rifamycin-quinolone hybrid agent with contributions from both of its composite pharmacophores. Against rifampin-susceptible strains, CBR-2092 exhibited bactericidal activity in vitro similar to that of rifampin, but FIG. 6 . In vitro intracellular killing activity. Changes in the number of intracellular S. aureus CB1406 (ATCC 25923) (A) or stable small colony variant CB1927 with a ⌬hemB::ermC deletion-replacement mutation (B) in infected J774A.1 murine macrophages with treatment with fixed doses of indicated antibiotics were determined. Viable CFU were recovered following deoxycholate-mediated cell disruption, serial dilution, and plating on charcoal agar medium. Survival or killing was expressed as the percent survival relative to the number of viable intracellular CFU at the start of the study. Symbols: closed squares, oxacillin (4 g/ml); closed circles, gentamicin (4 g/ml); open circles, CBR-2092 (4 g/ml); open triangles, rifampin (4 g/ml); closed triangles, moxifloxacin (4 g/ml); closed triangles, dashed line, rifampin (4 g/ml) plus moxifloxacin (4 g/ml).
with altered time and concentration dependence. Direct comparison of this time-kill behavior with the behaviors of equivalently dosed rifampin or ciprofloxacin suggests that CBR-2092 exhibits activity against fully susceptible strains at concentrations of Ն0.1 g/ml via its fluoroquinolone pharmacophore. Against rifampin-resistant strains, CBR-2092 exhibits rapid, fluoroquinolone-like killing activity that has elements of both time and concentration dependence. However, in this case, a paradoxical bactericidal effect was evident, with decreased killing observed at higher CBR-2092 concentrations. Paradoxical bactericidal effects are apparent for a number of quinolone agents and have been explained by a number of alternate theories (8) . Further studies will be necessary to address the mechanistic features underlying the apparent paradoxical killing properties observed with CBR-2092 and its potential clinical manifestations.
Both rifampin and CBR-2092 were observed to exhibit improved cidality against a susceptible S. epidermidis strain compared with that observed against S. aureus. Similar results have been reported from studies of the activities of rifamycins against S. epidermidis and other coagulase-negative staphylococci. However, under the conditions employed in the present study, CBR-2092 was found to be superior to rifampin in that no resistance development or rebound of treated cultures was observed in time-kill studies at doses above the MIC, and this differentiation presumably reflects the activity of the quinolone pharmacophore of CBR-2092. Overall, the reasons underlying the increased cidalities that both rifampin and CBR-2092 exhibit against S. epidermidis compared to those observed against S. aureus are unknown and are worthy of further investigation.
CBR-2092 exhibits PAEs and SMEs that are, overall, distinct from those previously described for members of the rifamycin and fluoroquinolone antibiotic classes. Under the conditions employed here, neither rifampin nor ciprofloxacin exhibited an SME. In striking contrast, the SME measured for CBR-2092 against S. aureus was 6.5 h, and its PA-SME (Ͼ8.5 h) was significantly prolonged over that observed with rifampin (3.9 h). Further studies will be necessary to address the mechanistic basis underlying the distinct difference between rifampin and CBR-2092 with regard to these parameters. However, the activity of efflux systems is known to be an important factor in determining PAEs for fluoroquinolones against S. aureus (1) and rifampin against Escherichia coli (22) . Hence, the apparent nonsusceptibility of CBR-2092 to either the intrinsic or the mutationally activated efflux systems of S. aureus that are active against fluoroquinolones may be one factor underlying the prolonged SMEs and PA-SMEs observed. As up to ϳ50% of fluoroquinolone-resistant clinical isolates of S. aureus exhibit an enhanced quinolone efflux phenotype (4, 20, 21, 23) , the prolonged SMEs and PA-SMEs observed with CBR-2092 may contribute to an activity profile that is distinct from that of rifamycin-fluoroquinolone cocktail combinations.
Aside from the aforementioned differentiation of CBR-2092 from rifamycin-fluoroquinolone cocktail combinations at the level of efflux, the studies reported here and elsewhere (19) highlight some additional instances in which the covalent linkage of these two pharmacophores appears to translate to an improved activity profile. First, CBR-2092 exhibits bactericidal activity (Ն99.9% at 24 h) at 0.25 or 4 g/ml in time-kill assays initiated at a high cell density and does not cause the development of either CBR-2092 or rifampin resistance (data not shown). As expected from past studies, a variety of fluoroquinolones dosed at concentrations corresponding to their individual CLSI resistance breakpoints similarly exhibit rapid bactericidal characteristics in this context, whereas rifampin alone (at 1 g/ml) is bacteriostatic and fails to suppress the outgrowth of a rifampin-resistant population. However, use of the combination of rifampin (at 1 g/ml) and the fluoroquinolones dosed at their CLSI resistance breakpoints is observed to have a dramatic effect on their cidality, with no combination achieving a killing of Ն99.9% at 24 h. In a related example, rifampin-mediated antagonism of the effective cidality of moxifloxacin is apparent in the intracellular killing assays undertaken with S. aureus CB1406 (Fig. 6A) . These data are consistent with past reports in the literature of the antagonism of the quinolone-mediated killing of staphylococci by rifamycins and translation inhibitors (6) (7) (8) and are consistent with the aforementioned mode of killing that requires the de novo synthesis of a quinolone lethality factor (8) .
Finally, CBR-2092 was found to exhibit intracellular killing activity against staphylococci, including an engineered small colony variant, that was improved over the killing activities of various comparator agents and a cocktail made up of rifampin plus moxifloxacin. The excellent activity of rifamycins against a number of intracellular pathogens has been well documented and presumably reflects the effective penetration of rifamycins into mammalian cells and relevant subcellular compartments and the essential nature of the transcription process in the propagation and/or persistence of bacteria in the intracellular environment (9) . Small colony variants of S. aureus (and other pathogens) have metabolic defects that confer a small colony phenotype in vitro and have been associated with a variety of persistent and recurrent diseases, including chronic osteomyelitis, cystic fibrosis, and infections of indwelling medical devices (17) . Aside from the increased expression of surface adhesion factors (17, 24) , staphylococcal small colony variants have been shown to exhibit improved intracellular persistence characteristics through protection from host immune defenses and reduced susceptibility to many classes of antibiotics (17, 25) . Indeed, one explanation for the recurrent nature of certain device-related infections is that S. aureus isolates persisting as small colony variants inside host cells both evade host immune factors and antibiotics and act as a seed reservoir for repeat infections (17) . The improved intracellular killing activity of CBR-2092 compared to that of rifampin from the in vitro studies described here, including the retention of activity against a prevalent auxotrophic class of small colony variant, holds promise for the potential utility of CBR-2092 in the treatment of recurrent and/or persistent infections mediated by susceptible gram-positive cocci for which intracellular reservoirs represent an important clinical manifestation.
